Brain+ meets milestone with Rox Health (Roche Germany)
- Rox Health has approved the German version of Brain+’s first digital dementia product, CST-Therapist Companion, for commercial launch.
- Meeting this milestone unlocks access for Brain+ to additional expert resources in the Rox Health/Roche organization and triggers a minor milestone payment.
- The following milestones will be product launch in Germany, targeted for Q2 2023, and getting the first German customers.
- The German market for digital dementia therapeutics is estimated at €400 million.
October 11, 2022 – Brain+, a pioneer in the development of digital therapeutics for Alzheimer’s disease and dementia, has met the first of three milestones in its partnership with Rox Health, the digital venture builder of Roche Germany The partnership was initiated in December 2021 to co-develop and commercialization Brain+’s portfolio of digital Cognitive Stimulation Therapy (CST) products in Germany.
The first milestone is the delivery and approval by Rox Health of a full German version of CST-Therapist Companion, which is the first of the CST products, Brain+ has in development. The next milestone under the partnership will be a product launch in the German market, which is planned for Q2 2023. A third milestone will be sale to the first customers in the estimated €400 million market for digital dementia therapeutics in Germany.
The approval by Rox Health brings us a big step closer to the planned launch of CST-Therapist Companion on the German market. The milestone is also evidence of Brain+’s ability to partner effectively with established pharma players to bring new innovative therapeutics efficiently to the market. Open access to the know-how of the Rox Health and Roche Germany organizations has tremendous value to a relatively small company like ours in achieving our big ambitions, and it is collaborations like these that make us to succeed.Kim Baden-Kristensen, Co-founder and CEO, Brain+
The collaboration with Brain+ is effective and enjoyable, bringing the best of both worlds to the table. The great unmet clinical need in dementia still stands unanswered and we still see a big need for solutions like the ones we are working on with Brain+. We believe that an eco-system approach to Alzheimer’s and dementia is needed, and we believe digital therapeutics will play an important role.Dr. Nikos Green, Senior Venture Architect & PO Neuroscience, Rox Health
Reimbursement in Germany is next
The initial sales model for the CST-Therapist Companion is a B2B subscription based SaaS model, and is initially paid for by individual clinics and care homes. In parallel with beginning the sales effort, Brain+ and Rox Health will be working to establish Brain+ products as reimbursable digital therapeutics at a national healthcare level in Germany, focusing initially on the CST-Therapist Companion, and the following product, CST-Home Care. This means that these products will be covered by the healthcare funds across all of Germany. Reimbursment of these products is achieved by taking the product through the new reimbursement pathway for digital care applications, DIPA (“Digitale Pflegeanwendungen“). Getting reimbursed via DIPA sets strict product quality requirements, and the Brain+ CST products are being developed in accordance to these strict requirements. Reimbursement will enable faster adoption of the CST-products and allow more widespread market penetration. DIPA supports reimbursement of up to €600 per year.